Search results for "DYSLIPIDEMIA"

showing 10 items of 287 documents

Is the Physician’s Behavior in Dyslipidemia Diagnosis in Accordance with Guidelines? Cross-Sectional Escarval Study

2013

Background: Clinical inertia has been defined as mistakes by the physician in starting or intensifying treatment when indicated. Inertia, therefore, can affect other stages in the healthcare process, like diagnosis. The diagnosis of dyslipidemia requires $ 2 high lipid values, but inappropriate behavior in the diagnosis of dyslipidemia has only previously been analyzed using just total cholesterol (TC). Objectives: To determine clinical inertia in the dyslipidemia diagnosis using both TC and high-density lipoprotein cholesterol (HDL-c) and its associated factors. Design: Cross-sectional. Setting: All health center visits in the second half of 2010 in the Valencian Community (Spain). Patient…

MaleHealth ScreeningNon-Clinical MedicineCross-sectional studyHealth Care ProvidersCardiovascularchemistry.chemical_compoundRisk FactorsOdds RatioPractice Patterns Physicians'Young adultHealth Systems StrengtheningMultidisciplinaryCommunicationQRAtrial fibrillationMiddle AgedCholesterolMedicineFemalelipids (amino acids peptides and proteins)Guideline AdherencePublic HealthResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignScienceCardiologyYoung AdultDiagnostic MedicinePhysiciansInternal medicineDiabetes mellitusmedicineHumansHealth Care QualityAgedDyslipidemiasHealth Care Policybusiness.industryCholesterolCholesterol HDLOdds ratiomedicine.diseaseMiddle ageCross-Sectional StudieschemistrySpainPreventive MedicinebusinessDyslipidemia
researchProduct

Association of Osteoarthritis with Increased Risk of Cardiovascular Diseases in the Elderly: Findings from the Progetto Veneto Anziano Study Cohort

2015

Objective The possible relevance of osteoarthritis (OA) as a cardiovascular disease (CVD) risk factor is still debated. The aim of this study was to investigate the association between OA and the onset of CVD in older individuals. Methods Among a sample of 3,099 elderly subjects, 2,158 were identified as having no CVD at baseline and were followed up for a mean ± SD 4.4 ± 1.2 years. OA was defined using a standardized algorithm that investigated disease history, medical documentation (including radiographic reports), symptoms, and physical examination of the joints. Incident CVD was defined as the onset of coronary artery disease, heart failure, stroke/transient ischemic attack, peripheral …

MaleIMPACTImmunologyUNITED-STATESPROGRESSIONCoronary Artery DiseaseKNEE OSTEOARTHRITISNOCohort StudiesPeripheral Arterial DiseaseRheumatologyImmunology; Immunology and Allergy; RheumatologyRisk FactorsOsteoarthritisEPIDEMIOLOGYHumansImmunology and AllergyObesityAgedDyslipidemiasProportional Hazards ModelsAged 80 and overHeart FailureDISABILITYMORTALITYIncidencePREVALENCEHospitalizationLipoproteins LDLStrokeATHEROSCLEROSISItalyCardiovascular DiseasesIschemic Attack TransientHypertensionFemaleARTHRITISFollow-Up Studies
researchProduct

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial

2012

Background The effects of different hypolipidemic treatment strategies on emerging atherosclerosis risk factors remain unknown. Materials and methods This is a prespecified analysis of a prospective, randomized, open-label, blinded end point (PROBE) study (ClinicalTrials.gov identifier: NCT01010516). Patients (n = 100) with mixed dyslipidaemia on a standard statin dose who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40 mg/day) or to add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (LRPT) or to add-on-statin micronized fenofibrate for a total of 3 months. Results Following 3 months of treatment, low-density lipoprotein (LDL) …

MaleIndolesTime FactorsClinical BiochemistryPilot ProjectsPharmacologyBiochemistryGastroenterologychemistry.chemical_compoundFenofibrateRisk FactorsProspective StudiesRosuvastatin CalciumHypolipidemic AgentsSulfonamidesFenofibratebiologyGeneral MedicineMiddle AgedRosuvastatin CalciumC-Reactive ProteinCardiovascular DiseasesDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Laropiprantmedicine.drugAdultmedicine.medical_specialtyStatinmedicine.drug_classNiacinInternal medicinemedicineHumansRosuvastatinAgedApolipoproteins BDyslipidemiasbusiness.industryCholesterolC-reactive proteinnutritional and metabolic diseasesCholesterol LDLAtherosclerosismedicine.diseaseFluorobenzenesPyrimidineschemistry1-Alkyl-2-acetylglycerophosphocholine Esterasebiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemiaEuropean Journal of Clinical Investigation
researchProduct

Prevalence of corneal arcus and associated factors in a German population-Results from the Gutenberg Health Study.

2021

Purpose We aimed to determine the prevalence of corneal arcus and to identify associated factors in the general population of Germany. Methods The Gutenberg Health Study (GHS) is a population-based cohort study in Germany, which includes an ophthalmological assessment. Refraction, distance-corrected visual acuity, non-contact tonometry and anterior segment imaging were performed for the five-year follow-up examination. Anterior segment photographs were graded for the presence of corneal arcus. Prevalence estimates were computed, and multivariable logistic regression analysis was applied to determine associated factors for corneal arcus including sex, age, spherical equivalent, central corn…

MaleIntraocular pressureVisual acuitygenetic structuresVisual AcuityBlood PressureCardiovascular MedicineBiochemistryVascular MedicineGeographical locationsCorneaMedical ConditionsEndocrinologyCorneaGermanyMedicine and Health SciencesPrevalenceProspective StudiesDioptreeducation.field_of_studyMultidisciplinaryQRMiddle AgedLipidsEuropemedicine.anatomical_structureCholesterolCardiovascular DiseasesMedicineFemalemedicine.symptomAnatomyCohort studyResearch Articlemedicine.medical_specialtyEndocrine DisordersOcular AnatomySciencePopulationCardiologyArcus SenilisOcular SystemOphthalmologymedicineDiabetes MellitusHumansEuropean UnioneducationIntraocular Pressurebusiness.industryBiology and Life SciencesCardiovascular Disease Riskmedicine.diseaseeye diseasesBlood pressureCross-Sectional StudiesMetabolic DisordersEyessense organsPeople and placesbusinessHeadDyslipidemiaPLoS ONE
researchProduct

Metabolic syndrome in the offspring of centenarians: focus on prevalence, components, and adipokines

2013

With aging, an increased prevalence of a clustering of metabolic abnormalities has been observed. These abnormalities include obesity, dyslipidemia, hypertension, and insulin resistance and are collectively known as metabolic syndrome (MetS), a low-grade, systemic, inflammatory condition associated with an increased risk of cardiovascular disease, diabetes, and other adverse health outcomes. A number of studies have demonstrated that centenarians’ offspring have a significant survival advantage and a lower risk of developing the most important age-related diseases. They therefore represent one of the best models with which to study the familiar component of human longevity. The aim of this …

MaleParentsmedicine.medical_specialtyAgingOffspringAdipokine030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineInsulin resistanceAdipokinesBETA-CELL FUNCTIONRisk FactorsInternal medicineDiabetes mellitusGROWTH-FACTOR-IPrevalenceMedicineHumans030304 developmental biologyAgedMetabolic SyndromeSettore MED/04 - Patologia Generale0303 health sciencesINSULIN-RESISTANCEbusiness.industryMetabolic syndrome Aging Inflammaging Centenarians’offspring Adipokines.General Medicinemedicine.diseaseObesityEndocrinologyItalyResistinFemaleGeriatrics and GerontologyMetabolic syndromebusinessDyslipidemia
researchProduct

Role of HDL function and LDL atherogenicity on cardiovascular risk: a comprehensive examination

2019

[Background] High-density lipoprotein (HDL) functionality and low-density lipoprotein (LDL) atherogenic traits can describe the role of both particles on cardiovascular diseases more accurately than HDL- or LDL-cholesterol levels. However, it is unclear how these lipoprotein properties are particularly affected by different cardiovascular risk factors.

MalePhysiologyhumanosLipoproteïnesBlood PressureCardiovascular Medicine030204 cardiovascular system & hematologyOxidacióBiochemistryVascular Medicinelipoproteínas616.1 - Patologia del sistema circulatori dels vasos sanguinis. Trastorns cardiovasculars:Ciencias de la Salud::Cardiología [Materias Investigacion]Endocrinology0302 clinical medicineRisk FactorsSex factorsSistema cardiovascular--MalaltiesMedicine and Health SciencesMedicine030212 general & internal medicinemediana edadancianoMultidisciplinaryQChemical ReactionsAge FactorsRMiddle AgedadultoLipidsBody FluidsLipoproteins LDLLipoproteïnes de densitat baixaChemistryBloodCholesterolCardiovascular DiseasesPhysical SciencesHypertensiondiabetes mellitusMedicineFemalelipids (amino acids peptides and proteins)AnatomyLipoproteins HDLColesterolResearch ArticleAdultEndocrine DisordersScienceLipoproteinsdislipidemiasenfermedades cardiovascularesBlood Plasma03 medical and health sciencesSex FactorsOxidationHumansfactores de riesgoAgedDyslipidemiasbusiness.industryCholesterol HDLBiology and Life SciencesProteinsCholesterol LDLAtherosclerosisSistema cardiovascular -- Malalties -- Factors de riscCross-Sectional StudiesLipoproteïnes de densitat altaDyslipidemiaDiabetes Mellitus Type 2Metabolic DisordersaterosclerosisbusinessHumanitiesestudios transversales
researchProduct

Adipose tissue in obesity and obstructive sleep apnoea

2011

A European Respiratory Society research seminar on ‘‘Metabolic alterations in obstructive sleep apnoea (OSA)’’ was jointly organised in October 2009 together with two EU COST actions (Cardiovascular risk in the obstructive sleep apnoea syndrome, action B26, and Adipose tissue and the metabolic syndrome, action BM0602) in order to discuss the interactions between obesity and OSA. Such interactions can be particularly significant in the pathogenesis of metabolic abnormalities and in increased cardiovascular risk in OSA patients. However, studying the respective role of OSA and obesity is difficult in patients, making it necessary to refer to animal models or in vitro systems. Since most OSA p…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyLipoxygenaseAdipose tissueMiceInsulin resistancestomatognathic systemAnimalsHumansMedicineObesityHypoxiaIntensive care medicineDyslipidemiasInflammationSleep Apnea Obstructivebusiness.industryAdipocyte dyslipidaemia hypoxia liver dysfunction obesitySleep apneaHypoxia (medical)medicine.diseaseObesitySleep in non-human animalsRatsnervous system diseasesrespiratory tract diseasesOxidative StressAdipose TissuePhysical therapyFemaleInsulin ResistanceLiver dysfunctionMetabolic syndromemedicine.symptombusinessEuropean Respiratory Journal
researchProduct

The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndro…

2010

The R3i Foundation (Residual Risk Reduction Initiative), an independent, multinational and academic organization, is conducting the REALIST (Residual Risk, Lipids and Standard Therapies) study in 40 centers in different countries. This is a retrospective epidemiological study, designed to provide new data on the residual risk of major coronary events attributable to lipid abnormalities in patients receiving the current standard treatment. The initial results are expected in mid 2010, and the overall results at the end of 2010.

MaleRiskmedicine.medical_specialtyAcute coronary syndromeInternational CooperationRisk AssessmentMedical RecordsMeta-Analysis as TopicRecurrenceInternal medicinemedicineHumansAcute Coronary SyndromeAgedDyslipidemiasRetrospective StudiesAged 80 and overHypertriglyceridemiamedicine.diagnostic_testbusiness.industryPatient SelectionStandard treatmentCholesterol HDLCase-control studyRetrospective cohort studyCholesterol LDLMiddle AgedAtherosclerosismedicine.diseaseLipidsSurgeryResidual riskCardiovascular DiseasesCase-Control StudiesFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profileRisk assessmentbusinessDyslipidemiaEndocrinología y Nutrición (English Edition)
researchProduct

Metabolic effects of the obstructive sleep apnea syndrome and cardiovascular risk

2008

The obstructive sleep apnea syndrome (OSAS) is characterized by collapse of the upper airway during sleep, recurring apneas, intermittent hypoxemia and daytime somnolence. OSAS is often associated with obesity, and its prevalence is expected to rise due to the obesity epidemics worldwide. OSAS is associated with increased cardiovascular risk which appears to be normalized by treatment with nasal continuous positive airway pressure (nCPAP) during sleep, suggesting an independent role of OSAS in accelerating atherosclerosis. Insulin resistance (IR) and the metabolic syndrome (MetS) are often found in OSAS patients, but the relative role played by OSAS and obesity is still unclear. Both OSAS a…

MaleRiskmedicine.medical_specialtySympathetic nervous systemPhysiologymedicine.medical_treatmentSettore MED/10 - Malattie Dell'Apparato RespiratorioGlucose metabolism dyslipidemia sleep loss animal models children adipocyteHypoxemiaInsulin resistancestomatognathic systemPhysiology (medical)Internal medicineAdipocytesmedicineAnimalsHumansObesityContinuous positive airway pressureChildInflammationSleep Apnea Obstructivebusiness.industryGeneral Medicinemedicine.diseaseObesitynervous system diseasesrespiratory tract diseasesObstructive sleep apneaDisease Models AnimalGlucosemedicine.anatomical_structureEndocrinologyAdipose TissueCardiovascular DiseasesCardiologyMetabolic syndromemedicine.symptombusinessDyslipidemiaArchives of Physiology and Biochemistry
researchProduct

Under-prescription of statins in patients with non-alcoholic fatty liver disease

2017

Abstract Background and Aim Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with high cardiovascular risk. Management of dyslipidaemia plays a pivotal role in the prevention of CV events and statins have proved to be safe in these patients. However, in everyday clinical practice statin prescription is sometimes limited because of the concern of physicians about side-effects. The aim of the study was to investigate if the presence of NAFLD affects the prescription of lipid-lowering treatment in a large series of patients with cardio-metabolic disorders. Methods and Results Cardiovascular risk and LDL-C targets were defined according to ESC/EAS Guidelines in 605 conse…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Disease030204 cardiovascular system & hematologyEndocrinology0302 clinical medicineDrug PrescriptionNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseNutrition and DieteticPractice Patterns Physicians'Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedDiabetes and MetabolismCardiovascular DiseasesPractice Guidelines as TopicCohortUnder-prescriptionFemalelipids (amino acids peptides and proteins)030211 gastroenterology & hepatologyGuideline AdherenceCardiology and Cardiovascular MedicineHumanAdultCardiovascular risk; Non-alcoholic fatty liver disease; Statins; Under-prescription; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyStatinmedicine.drug_classContext (language use)Health Services MisuseDrug Prescriptions03 medical and health sciencesInternal medicinemedicineHumansMedical prescriptionAgedDyslipidemiasCross-Sectional Studiebusiness.industryRisk FactorStatinsStatinnutritional and metabolic diseasesNon alcoholicBiomarkerCholesterol LDLCardiovascular riskmedicine.diseaseCross-Sectional StudiesDyslipidemiaPhysical therapyHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profilebusinessBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct